Pulmonary Disease in Cystic Fibrosis

Kendig and Chernick's Disorders of the Respiratory Tract in Children

Volumn , Issue , 2012, Pages 770-780

  Faro, Albert ^a   Michelson, Peter H ^a   Ferkol, Thomas W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882928376     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1984-0.00052-8     Document Type: Chapter

References (171)

1. J.F. Chmiel, M. Berger and M.W. Konstan (2002) The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol. 23 5-27.
2. P.B. Davis (2006) Cystic fibrosis since 1938. Am J Respir Crit Care Med. 173 475-482.
3. A. Elizur, C.L. Cannon and T.W. Ferkol (2008) Airway inflammation in cystic fibrosis. Chest 133 489-495.
4. T. Ferkol, M. Rosenfeld and C.E. Milla (2006) Cystic fibrosis pulmonary exacerbations. J Pediatr. 148 259-264.
5. P.A. Flume, B.P. O'Sullivan, K.A. Robinson, et al. (2007) Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 176 957-969.
6. R.L. Gibson, J.L. Burns and B.W. Ramsey (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 168 918-951.
7. M.R. Knowles and R.C. Boucher (2002) Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest. 109 571-577.
8. B.P. O'Sullivan and S.D. Freedman (2009) Cystic fibrosis. Lancet. 373 1891-1904.
9. S.M. Rowe, S. Miller and E.J. Sorscher (2005) Cystic fibrosis. N Engl J Med. 352 1992-2001.
10. Cystic Fibrosis Foundation (2009) Cystic Fibrosis Foundation Patient Registry, 2008 Annual Data Report. Bethesda, MD
11. A.S. Verkman, Y. Song and J.R. Thiagarajah (2003) Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease. Am J Physiol Cell Physiol. 284 C2-C15.
12. M.R. Knowles and R.C. Boucher (2002) Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest. 109 571-577.
13. H. Matsui, B.R. Grubb, R. Tarran, et al. (1998) Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95 1005-1015.
14. J.J. Wine (1999) The genesis of cystic fibrosis lung disease. J Clin Invest. 103 309-312.
15. J.J. Smith, S.M. Travis, E.P. Greenberg, et al. (1996) Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85 229-236.
16. E. DiMango, A.J. Ratner, R. Bryan, et al. (1998) Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest. 101 2598-2605.
17. G.B. Pier, M. Grout and T.S. Zaidi (1997) Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci U S A 94 12088-12093.
18. R.L. Gibson, J.L. Burns and B.W. Ramsey (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 168 918-951.
19. T.Z. Khan, J.S. Wagener, T. Bost, et al. (1995) Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 151 1075-1082.
20. M.S. Muhlebach, P.W. Stewart, M.W. Leigh, et al. (1999) Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med. 160 186-191.
21. K. Balough, M. McCubbin, M. Weinberger, et al. (1995) The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol. 20 63-70.
22. D.S. Armstrong, K. Grimwood, J.B. Carlin, et al. (1997) Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med. 156 1197-1204.
23. J.B. Lyczak, C.L. Cannon and G.B. Pier (2002) Lung infections associated with cystic fibrosis. Clin Microbiol Rev. 15 194-222.
24. E.C. Dasenbrook, W. Checkley, C.A. Merlo, et al. (2010) Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA. 303 2386-2392.
25. A.F. Barker (2002) Bronchiectasis. N Engl J Med. 346 1383-1393.
26. P.K. Singh, A.L. Schaefer, M.R. Parsek, et al. (2000) Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407 762-764.
27. E. Drenkard and F.M. Ausubel (2002) Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416 740-743.
28. N. Hoiby, B. Frederiksen and T. Pressler (2005) Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros. 4(suppl 2), 49-54.
29. M.M. Treggiari, M. Rosenfeld, N. Mayer-Hamblett, et al. (2009) Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study’. Contemp Clin Trials 30 256-268.
30. C.H. Goss, K. Otto, M.L. Aitken, et al. (2002) Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med. 166 356-361.
31. A. Isles, I. Maclusky, M. Corey, et al. (1984) Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr. 104 206-210.
32. E. Mahenthiralingam, P. Vandamme, M.E. Campbell, et al. (2001) Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis. 33 1469-1475.
33. L.A. Kalish, D.A. Waltz, M. Dovey, et al. (2006) Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med. 173 421-425.
34. K.N. Olivier, D.J. Weber, R.J. Wallace Jr, et al. (2003) Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med. 167 828-834.
35. P.W. Hiatt, S.C. Grace, C.A. Kozinetz, et al. (1999) Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 103 619-626.
36. S.Z. Wang, H. Xu, A. Wraith, et al. (1998) Neutrophils induce damage to respiratory epithelial cells infected with respiratory syncytial virus. Eur Respir J. 12 612-618.
37. J. Tseng, J. Do, J.H. Widdicombe, et al. (2006) Innate immune responses of human tracheal epithelium to Pseudomonas aeruginosa flagellin, TNF-alpha, and IL-1beta. Am J Physiol Cell Physiol. 290 C678-C690.
38. R. Tarran, B. Button, M. Picher, et al. (2005) Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections. J Biol Chem. 280 35751-35759.
39. M.W. Konstan, K.A. Hilliard, T.M. Norvell, et al. (1994) Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med. 150 448-454.
40. P. Birrer, N.G. McElvaney, A. Rudeberg, et al. (1994) Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med. 150 207-213.
41. A. Elizur, C.L. Cannon and T.W. Ferkol (2008) Airway inflammation in cystic fibrosis. Chest 133 489-495.
42. T.L. Bonfield, J.R. Panuska, M.W. Konstan, et al. (1995) Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med. 152 2111-2118.
43. J.F. Chmiel, M. Berger and M.W. Konstan (2002) The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol. 23 5-27.
44. R.B. Fick Jr, R.A. Robbins, S.U. Squier, et al. (1986) Complement activation in cystic fibrosis respiratory fluids: in vivo and in vitro generation of C5a and chemotactic activity. Pediatr Res. 20 1258-1268.
45. F. McAllister, A. Henry, J.L. Kreindler, et al. (2005) Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol. 175 404-412.
46. A. Venkatakrishnan, A.A. Stecenko, G. King, et al. (2000) Exaggerated activation of nuclear factor-kappaB and altered IkappaB-beta processing in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol. 23 396-403.
47. T.S. Blackwell, A.A. Stecenko and J.W. Christman (2001) Dysregulated NF-kappaB activation in cystic fibrosis: evidence for a primary inflammatory disorder. Am J Physiol Lung Cell Mol Physiol. 281 L69-L70.
48. O. Tabary, S. Escotte, J.P. Couetil, et al. (2001) Relationship between IkappaBalpha deficiency, NFkappaB activity and interleukin-8 production in CF human airway epithelial cells. Pflugers Arch. 443(suppl), S40-S44.
49. J.Y. Lee, H.L. Elmer, K.R. Ross, et al. (2004) Isoprenoid-mediated control of SMAD3 expression in a cultured model of cystic fibrosis epithelial cells. Am J Respir Cell Mol Biol. 31 234-240.
50. D. Kube, U. Sontich, D. Fletcher, et al. (2001) Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines. Am J Physiol Lung Cell Mol Physiol. 280 L493-L502.
51. T.L. Bonfield, M.W. Konstan and M. Berger (1999) Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol. 104 72-78.
52. N. Aldallal, E.E. McNaughton, L.J. Manzel, et al. (2002) Inflammatory response in airway epithelial cells isolated from patients with cystic fibrosis. Am J Respir Crit Care Med. 166 1248-1256.
53. M.N. Becker, M.S. Sauer, M.S. Muhlebach, et al. (2004) Cytokine secretion by cystic fibrosis airway epithelial cells. Am J Respir Crit Care Med. 169 645-653.
54. M.M. Farberman, A. Ibricevic, T.D. Joseph, et al. (2010) The effect of polarized release of CXC-chemokines from wild-type and cystic fibrosis murine airway epithelial cells. Am J Respir Cell Mol Biol e-pub Jul 16
55. A. Belaaouaj, R. McCarthy, M. Baumann, et al. (1998) Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med. 4 615-618.
56. C.M. O'Connor, K. Gaffney, J. Keane, et al. (1993) Alpha 1-Proteinase inhibitor, elastase activity, and lung disease severity in cystic fibrosis. Am Rev Respir Dis. 148 1665-1670.
57. H. Nakamura, K. Yoshimura, N.G. McElvaney, et al. (1992) Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest. 89 1478-1484.
58. M.F. Tosi, H. Zakem and M. Berger (1990) Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest. 86 300-308.
59. R.B. Fick Jr, G.P. Naegel, S.U. Squier, et al. (1984) Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J Clin Invest. 74 236-248.
60. T. Tomashefski and D. Dail (2008) Aspiration, bronchial obstruction, bronchiectasis, and related disorders. Nonneoplastic Lung Disease. Vol 1 New York City, NY: Springer Science
61. T. Ferkol and P. Davis (1998) Bronchiectasis and bronchiolitis obliterans. Textbook of Pediatric Respiratory Medicine. St Louis: Mosby Year Book
62. T. Ferkol, M. Rosenfeld and C.E. Milla (2006) Cystic fibrosis pulmonary exacerbations. J Pediatr. 148 259-264.
63. R.E. Wood and M.W. Leigh (1987) What is a “pulmonary exacerbation” in cystic fibrosis? J Pediatr. 111 841-842.
64. R. Cepero, R.J. Smith, F.I. Catlin, et al. (1987) Cystic fibrosis—an otolaryngologic perspective. Otolaryngol Head Neck Surg. 97 356-360.
65. G. Henriksson, K.M. Westrin, F. Karpati, et al. (2002) Nasal polyps in cystic fibrosis: Clinical endoscopic study with nasal lavage fluid analysis. Chest 121 40-47.
66. A. Jung, I. Kleinau, G. Schonian, et al. (2002) Sequential genotyping of Pseudomonas aeruginosa from upper and lower airways of cystic fibrosis patients. Eur Respir J. 20 1457-1463.
67. R.C. Stern, T.F. Boat, R.E. Wood, et al. (1982) Treatment and prognosis of nasal polyps in cystic fibrosis. Am J Dis Child. 136 1067-1070.
68. P.A. Flume, P.J. Mogayzel Jr, K.A. Robinson, et al. (2010) Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. e-pub Mar 18
69. D.V. Schidlow, L.M. Taussig and M.R. Knowles (1993) Cystic Fibrosis Foundation consensus conference report on pulmonary complications of cystic fibrosis. Pediatr Pulmonol. 15 187-198.
70. G.M. Brinson, P.G. Noone, M.A. Mauro, et al. (1998) Bronchial artery embolization for the treatment of hemoptysis in patients with cystic fibrosis. Am J Respir Crit Care Med. 157 1951-1958.
71. P. Hiatt, H. Eigen, P. Yu, et al. (1988) Bronchodilator responsiveness in infants and young children with cystic fibrosis. Am Rev Respir Dis. 137 119-122.
72. P.L. Brand (2000) Bronchodilators in cystic fibrosis. J R Soc Med. 93(suppl), 37-39.
73. M. Silverman, F.D. Hobbs, I.R. Gordon, et al. (1978) Cystic fibrosis, atopy, and airways lability. Arch Dis Child 53 873-877.
74. C.M. Mellis and H. Levison (1978) Bronchial reactivity in cystic fibrosis. Pediatrics 61 446-450.
75. D.A. Stevens, R.B. Moss, V.P. Kurup, et al. (2003) Allergic bronchopulmonary aspergillosis in cystic fibrosis–state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis. 37(suppl), S225-S264.
76. T. Hilliard, S. Edwards, R. Buchdahl, et al. (2005) Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros. 4 215-220.
77. G. Steinkamp and B. Wiedemann (2002) Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax 57 596-601.
78. C.E. Milla, W.J. Warwick and A. Moran (2000) Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med. 162 891-895.
79. J. Emerson, M. Rosenfeld, S. McNamara, et al. (2002) Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 34 91-100.
80. G.M. Nixon, D.S. Armstrong, R. Carzino, et al. (2001) Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 138 699-704.
81. M.J. Thomassen, C.A. Demko, J.D. Klinger, et al. (1985) Pseudomonas cepacia colonization among patients with cystic fibrosis. A new opportunist. Am Rev Respir Dis. 131 791-796.
82. C.A. Demko, P.J. Byard and P.B. Davis (1995) Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol. 48 1041-1049.
83. A. Bush and C. Wallis (2000) Time to think again: cystic fibrosis is not an “all or none” disease. Pediatr Pulmonol. 30 139-144.
84. A.L. Quittner, M.S. Schechter, L. Rasouliyan, et al. (2010) Impact of socioeconomic status, race, and ethnicity on quality of life in patients with cystic fibrosis in the United States. Chest 137 642-650.
85. M.S. Schechter (2003) Non-genetic influences on cystic fibrosis lung disease: the role of sociodemographic characteristics, environmental exposures, and healthcare interventions. Semin Respir Crit Care Med. 24 639-652.
86. M.W. Konstan, S.M. Butler, M.E. Wohl, et al. (2003) Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr. 142 624-630.
87. A.S. Brody (1998) Cystic fibrosis: when should high-resolution computed tomography of the chest be obtained? Pediatrics 101 1071.
88. A.S. Brody, H.A. Tiddens, R.G. Castile, et al. (2005) Computed tomography in the evaluation of cystic fibrosis lung disease. Am J Respir Crit Care Med. 172 1246-1252.
89. S.D. Davis, L.A. Fordham, A.S. Brody, et al. (2007) Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. Am J Respir Crit Care Med. 175 943-950.
90. P.A. de Jong, H.A. Tiddens, M.H. Lequin, et al. (2008) Estimation of the radiation dose from CT in cystic fibrosis. Chest 133 1289-1291.
91. E. Kerem, J. Reisman, M. Corey, et al. (1992) Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 326 1187-1191.
92. M. Corey, L. Edwards, H. Levison, et al. (1997) Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr. 131 809-814.
93. P.B. Davis, P.J. Byard and M.W. Konstan (1997) Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res. 41 161-165.
94. M. Rosenfeld, J. Emerson, F. Accurso, et al. (1999) Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol. 28 321-328.
95. S.D. Sagel, M.K. Sontag, J.S. Wagener, et al. (2002) Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J Pediatr. 141 811-817.
96. B.P. O'Sullivan and S.D. Freedman (2009) Cystic fibrosis. Lancet. 373 1891-1904.
97. P.B. Davis (2006) Cystic fibrosis since 1938. Am J Respir Crit Care Med. 173 475-482.
98. F. Ratjen (2009) Update in cystic fibrosis 2008. Am J Respir Crit Care Med. 179 445-448.
99. M.K. Lester and P.A. Flume (2009) Airway-clearance therapy guidelines and implementation. Respir Care 54 733-750.
100. G. Pisi and A. Chetta (2009) Airway clearance therapy in cystic fibrosis patients. Acta Biomed. 80 102-106.
101. P. Flume, K. Robinson, B. O'Sullivan, et al. (2009) Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 54 522-537.
102. F. Ratjen (2008) Recent advances in cystic fibrosis. Paediatr Respir Rev. 9 144-148.
103. A.M. Jones and J.M. Helm (2009) Emerging treatments in cystic fibrosis. Drugs 69 1903-1910.
104. J.A. Pryor, E. Tannenbaum, S.F. Scott, et al. (2010) Beyond postural drainage and percussion: Airway clearance in people with cystic fibrosis. J Cyst Fibros. 9 187-192.
105. L. Lannefors, B.M. Button and M. McIlwaine (2004) Physiotherapy in infants and young children with cystic fibrosis: current practice and future developments. J R Soc Med. 97(suppl 44), 8-25.
106. M. McIlwaine (2007) Chest physical therapy, breathing techniques and exercise in children with CF. Paediatr Respir Rev. 8 8-16.
107. J.H. Marks (2007) Airway clearance devices in cystic fibrosis. Paediatr Respir Rev. 8 17-23.
108. F.D. McCool and M.J. Rosen (2006) Nonpharmacologic airway clearance therapies. Chest 129(suppl), 250S-259S.
109. C. van der Schans, A. Prasad and E. Main (2000) Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis. Cochrane Database Syst Rev. 2 CD001401
110. N. van Doorn (2010) Exercise programs for children with cystic fibrosis: A systematic review of randomized controlled trials. Disabil Rehabil. 32 41-49.
111. P. Anderson (2010) Emerging therapies in cystic fibrosis. Ther Adv Respir Dis. 4 177-185.
112. E.T. Zemanick, J.K. Harris, S. Conway, et al. (2009) Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy. J Cyst Fibros. 9 1-16.
113. A. Jaques, E. Daviskas, J.A. Turton, et al. (2008) Inhaled mannitol improves lung function in cystic fibrosis. Chest 133 1388-1396.
114. M.R. Elkins, M. Robinson, B.R. Rose, et al. (2006) A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 354 229-240.
115. E.P. Dellon, S.H. Donaldson, R. Johnson, et al. (2008) Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. Pediatr Pulmonol. 43 1100-1106.
116. C. Halfhide, H. Evans and J. Couriel (2005) Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev. 4 CD003428
117. B.K. Rubin (2009) Mucus, phlegm and sputum in cystic fibrosis. Respir Care 54 726-732.
118. M.O. Henke and F. Ratjen (2007) Mucolytics in cystic fibrosis. Paediatr Respir Rev. 8 24-29.
119. Y. Duijvestijn and P. Brand (1999) Systematic review of N-acetylcysteine in cystic fibrosis. Acta Pædiatr. 88 38-41.
120. N. Hoiby (1993) Antibiotic therapy for chronic infection of pseudomonas in the lung. Annu Rev Med. 44 1-10.
121. R.L. Gibson, J. Emerson, S. McNamara, et al. (2003) Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 167 841-849.
122. B. Frederiksen, C. Koch and N. Høiby (1997) Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 23 330-335.
123. N.H. Valerius, C. Koch and N. Hoiby (1991) Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 338 725-726.
124. F. Ratjen, A. Munck, P. Kho, et al. (2010) Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 65 286-291.
125. S.D. Aaron, K.L. Vandemheen, W. Ferris, et al. (2005) Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet. 366 463-471.
126. J. Prandota (1987) Drug disposition in cystic fibrosis: progress in understanding pathophysiology and pharmacokinetics. Pediatr Infect Dis J. 6 1111-1126.
127. B.A. Cunha (2002) Pseudomonas aeruginosa: resistance and therapy. Semin Respir Infect. 17 231-239.
128. B. Fernandes, A. Plummer and M. Wildman (2008) Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev. 2 CD006682
129. B.W. Ramsey, M.S. Pepe, J.M. Quan, et al. (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 340 23-30.
130. G.Z. Retsch-Bogart, A.L. Quittner, R.L. Gibson, et al. (2009) Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 135 1223-1232.
131. T. Jensen, S.S. Pedersen, S. Garne, et al. (1987) Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother. 19 831-838.
132. L.A. Whittaker and C. Teneback (2009) Atypical mycobacterial and fungal infections in cystic fibrosis. Semin Respir Crit Care Med. 30 539-546.
133. K.N. Olivier, D.J. Weber, J.H. Lee, et al. (2003) Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med. 167 835-840.
134. W.J. Matthews Jr, M. Williams, B. Oliphint, et al. (1980) Hypogammaglobulinemia in patients with cystic fibrosis. N Engl J Med. 302 245-249.
135. H. Auerbach, M. Williams, J. Kirkpatrick, et al. (1985) Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet. 2 686-688.
136. H. Eigen, B.J. Rosenstein, S. FitzSimmons, et al. (1995) A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr. 126 515-523.
137. I.M. Balfour-Lynn and K. Welch (2009) Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev. CD001915
138. M.W. Konstan, P.J. Byard, C.L. Hoppel, et al. (1995) Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 332 848-854.
139. L. Saiman, B.C. Marshall, N. Mayer-Hamblett, et al. (2003) Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 290 1749-1756.
140. L. Saiman, M. Anstead, N. Mayer-Hamblett, et al. (2010) Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 303 1707-1715.
141. R. Tirouvanziam, C.K. Conrad, T. Bottiglieri, et al. (2006) High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A. 103 4628-4633.
142. N.G. McElvaney, R.C. Hubbard, P. Birrer, et al. (1991) Aerosol α1-antitrypsin treatment of cystic fibrosis. Lancet. 337 392-394.
143. S. Schmitt-Grohé and S. Zielen (2005) Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects. Paediatr Drugs. 7 353-363.
144. R.B. Moss, N. Mayer-Hamblett, J. Wagener, et al. (2005) Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol. 39 209-218.
145. P. Dharmaraj and R.L. Smyth (2009) Vaccines for preventing influenza in people with cystic fibrosis. Cochrane Database Syst Rev. 4 CD001753
146. J.R. Ortiz, K.M. Neuzil, J.C. Victor, et al. (2010) Influenza-associated cystic fibrosis pulmonary exacerbations. Chest. 137 852-860.
147. K.A. Robinson, O.A. Odelola, I. Saldanha, et al. (2010) Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev. 2 CD007743
148. P.M. Farrell, M.R. Kosorok, M.J. Rock, et al. (2001) Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Pediatrics. 107 1-13.
149. K.W. Southern, M.M. Merelle, J.E. Dankert-Roelse and A.D. Nagelkerke (2009) Newborn screening for cystic fibrosis. Cochrane Database Syst Rev. 1 CD001402
150. E.J. Sims, A. Clark, J. McCormick, et al. (2007) Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy. Pediatrics. 119 19-28.
151. H.R. Stutman, J.M. Lieberman, E. Nussbaum, et al. (2002) Antibiotic prophylaxis in infants and young children with cystic fibrosis: A randomized controlled trial. J Pediatr. 140 299-305.
152. A. Smyth and S. Walters (2003) Prophylactic antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 3 CD001912
153. H.K. Johansen and P.C. Gotzsche (2008) Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev. 4 CD001399
154. M. Jain and A.H. Thomson (2009) Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis. J R Soc Med. 102(suppl), 23-28.
155. B. Stuart, J.H. Lin and P.J. Mogayzel Jr (2010) Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. Paediatr Respir Rev. 11 177-184.
156. P. Aurora, L.B. Edwards, J.D. Christie, et al. (2009) Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Lung and Heart/Lung Transplantation Report 2009. J Heart Lung Transplant. 28 1023-1030.
157. T.G. Liou, F.R. Adler, S.C. Fitzsimmons, et al. (2001) Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 153 345-352.
158. T.M. Egan, S. Murray, R.T. Bustami, et al. (2006) Development of the new lung allocation system in the United States. Am J Transplant. 6 1212-1227.
159. A. Elizur, S.C. Sweet, C.B. Huddleston, et al. (2007) Pre-transplant mechanical ventilation increases short-term morbidity and mortality in pediatric patients with cystic fibrosis. J Heart Lung Transplant. 26 127-131.
160. A. Faro, R. Shepherd, C.B. Huddleston, et al. (2007) Lower incidence of bronchiolitis obliterans in pediatric liver-lung transplant recipients with cystic fibrosis. Transplantation. 83 1435-1439.
161. J.C. Magee, S.M. Krishnan, M.R. Benfield, et al. (2008) Pediatric transplantation in the United States, 1997-2006. Am J Transplant. 8 935-945.
162. F.R. Adler, P. Aurora, D.H. Barker, et al. (2009) Lung transplantation for cystic fibrosis. Proc Am Thorac Soc. 6 619-633.
163. T.G. Liou, F.R. Adler, D.R. Cox, et al. (2007) Lung transplantation and survival in children with cystic fibrosis. N Engl J Med. 357 2143-2152.
164. S.C. Sweet, P. Aurora, C. Benden, et al. (2008) Lung transplantation and survival in children with cystic fibrosis: solid statistics—flawed interpretation. Pediatr Transplant. 12 129-136.
165. P. Aurora, B. Whitehead, A. Wade, et al. (1999) Lung transplantation and life extension in children with cystic fibrosis. Lancet. 354 1591-1593.
166. B. Smeritschnig, P. Jaksch, A. Kocher, et al. (2005) Quality of life after lung transplantation: a cross-sectional study. J Heart Lung Transplant. 24 474-480.
167. E. Kerem, S. Hirawat, S. Armoni, et al. (2008) Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 372 719-727.
168. F. Van Goor, K.S. Straley, D. Cao, et al. (2006) Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol. 290 L1117-L1130.
169. F. Van Goor, S. Hadida, P.D. Grootenhuis, et al. (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 106 18825-18830.
170. R.R. Deterding, L.M. LaVange, J.M. Engels, et al. (2007) Phase 2 Randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med. 176 362-369.
171. H. Grasemann, F. Stehling, H. Brunar, et al. (2007) Inhalation of Moli 1901 in patients with cystic fibrosis. Chest 131 1461-1466.